APVO - Aptevo Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aptevo Therapeutics Inc.

2401 4th Avenue
Suite 1050
Seattle, WA 98121
United States
206-838-0500
http://aptevotherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees118

Key Executives

NameTitlePayExercisedYear Born
Mr. Marvin L. WhitePres, CEO & Director786.71kN/A1962
Mr. Jeffrey G. LamotheSr. VP, CFO & Treasurer550.56kN/A1966
Dr. Scott C. StromattSr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer567.45kN/A1958
Mr. Randy Joe MadduxSr. VP of Operations & Chief Manufacturing OfficerN/AN/A1961
Dr. Jane A. GrossSr. VP & Chief Scientific OfficerN/AN/A1957
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome; APVO210, an anti-inflammatory molecule that is in pre-clinical development stage for the treatment of autoimmune and inflammatory diseases; ALG.APV-527, a bispecific antibody to target T cells; ROR1 Bispecific, a proof-of-concept bispecific candidate that is in preclinical development; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Corporate Governance

Aptevo Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.